Literature DB >> 20065085

Molecular or cytogenetic monitoring and preemptive therapy for central nervous system relapse of acute promyelocytic leukemia.

Sumimasa Nagai, Yasuhito Nannya, Shunya Arai, Yumiko Yoshiki, Tsuyoshi Takahashi, Mineo Kurokawa.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20065085      PMCID： PMC2805745          DOI： 10.3324/haematol.2009.015545

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

1.  Early detection of central nervous system relapse by polymerase chain reaction in children with B-precursor acute lymphoblastic leukemia.

Authors:  V de Haas; R J W M Vet; O J H M Verhagen; W Kroes; H van den Berg; C E van der Schoot
Journal:  Ann Hematol       Date:  2001-12-12       Impact factor: 3.673

Review 2.  A better way to find tumor in the CSF?

Authors:  Lisa M DeAngelis; J Gregory Cairncross
Journal:  Neurology       Date:  2002-02-12       Impact factor: 9.910

3.  Simultaneous appearance of central nervous system relapse and subarachnoid hemorrhage during the treatment for acute promyelocytic leukemia.

Authors:  Sumimasa Nagai; Takashi Asai; Takuro Watanabe; Kumi Oshima; Akira Hangaishi; Yoshinobu Kanda; Toru Motokura; Shigeru Chiba; Shigeki Aoki; Kuni Ohtomo; Mineo Kurokawa
Journal:  Ann Hematol       Date:  2008-01-18       Impact factor: 3.673

4.  Treatment of leptomeningeal metastases evaluated by interphase cytogenetics.

Authors:  R J van Oostenbrugge; A H Hopman; J W Arends; F C Ramaekers; A Twijnstra
Journal:  J Clin Oncol       Date:  2000-05       Impact factor: 44.544

5.  Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups.

Authors:  M A Sanz; F Lo Coco; G Martín; G Avvisati; C Rayón; T Barbui; J Díaz-Mediavilla; G Fioritoni; J D González; V Liso; J Esteve; F Ferrara; P Bolufer; C Bernasconi; M Gonzalez; F Rodeghiero; D Colomer; M C Petti; J M Ribera; F Mandelli
Journal:  Blood       Date:  2000-08-15       Impact factor: 22.113

6.  CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes.

Authors:  B Gleissner; J Siehl; A Korfel; R Reinhardt; E Thiel
Journal:  Neurology       Date:  2002-02-12       Impact factor: 9.910

7.  Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis.

Authors:  Pau Montesinos; Joaquín Díaz-Mediavilla; Guillermo Debén; Virginia Prates; Mar Tormo; Vicente Rubio; Inmaculada Pérez; Isolda Fernández; Maricruz Viguria; Chelo Rayón; José González; Javier de la Serna; Jordi Esteve; Juan M Bergua; Concha Rivas; Marcos González; Jose D González; Silvia Negri; Salut Brunet; Bob Lowenberg; Miguel A Sanz
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

Review 8.  Beneficial and adverse effects of molecularly targeted therapies for acute promyelocytic leukemia in central nervous system.

Authors:  Sumimasa Nagai; Tsuyoshi Takahashi; Mineo Kurokawa
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-11       Impact factor: 4.388

9.  Early detection of meningeal localization in acute promyelocytic leukaemia patients with high presenting leucocyte count.

Authors:  Massimo Breccia; Ida Carmosino; Daniela Diverio; Silvia De Santis; Maria Stefania De Propris; Atelda Romano; Maria C Petti; Franco Mandelli; Francesco Lo-Coco
Journal:  Br J Haematol       Date:  2003-01       Impact factor: 6.998
  9 in total
  2 in total

1.  Acute promyelocytic leukemia harbouring rare FLT3-TKD and WT1 mutations: A case report.

Authors:  Ting-Ting Liu; K E Zeng; Lin Wang; Ting Liu; Ting Niu
Journal:  Oncol Lett       Date:  2015-06-30       Impact factor: 2.967

2.  Central nervous system relapse in CD56+, FLT3/ITD+ promyelocytic leukemia.

Authors:  N Colovic; D Tomin; A Vidovic; N Tosic; H D Atkinson; Milica D Colovic
Journal:  Med Oncol       Date:  2011-02-05       Impact factor: 3.064
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.